Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Blocking Interfering Microbes: Irinotecan is a widely used anticancer pro-drug that is converted in the liver into the active form, but when it gets into the gut, the normally benign microbial flora can convert it into the toxic form, which kills the rapidly multiplying gut epithelium as it would kill rapidly dividing tumor cells, and thus causes diarrhea. Wallace et al. (p. 831 ; see the Perspective by Patel and Kaufmann ) used high-throughput screening to identify inhibitors that target the offending bacterial enzyme, β-glucuronidase, without killing the bacteria or affecting orthologous mammalian enzymes. Crystal structures revealed the molecular basis of selectivity, and in vivo studies showed that an inhibitor protected mice from irinotecan-induced toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“Toxic or adverse consequences can also ensue, as is the case for irinotecan (Wallace et al., 2010)”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
In the citing paper
“Notably, β-glucuronidase inhibitors are capable of rescuing mice from drug toxicity.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“This specificity towards the bacterial enzymes was revealed with the assistance of crystallography and bioinformatics, which demonstrated that these inhibitors interacted with a “bacterial loop” that is highly conserved and well distributed across the gut bacteria enzymes, but is absent from the mammalian enzyme146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“The answer appears to be yes for the bacterial β-glucuronidases, for which multiple inhibitors now exist that have minimal impact on the mammalian homolog143–146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
CDD: specific functional annotation with the Conserved Domain Database
Marchler-Bauer, A., Anderson, J. B., Chitsaz, F., Derbyshire, M. K., DeWeese-Scott, C., Fong, J. H., Geer, L. Y., Geer, R. C., Gonzales, N. R., Gwadz, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn845 · Cited by 1,071
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Three-dimensional structure of β-galactosidase from E. coli.
Jacobson, R. H., Zhang, X.-J., DuBose, R. F., & Matthews, B. W. (1994) · Nature · doi:10.1038/369761a0 · Cited by 600
Research works printed but not linked: 4
- Mathijssen RHJ Clin Cancer Res 7 2182 2001 11489791
- Basińska A Floriańczyk B Ann Univ Mariae Curie Sklodowska Med 58 386 2003 15323223
- Jain S Nat Struct Mol Biol 3 375 1996 · DOI · Paper page
- Brattain MG Fine WD Khaled FM Thompson J Brattain DE Cancer Res 41 1751 1981 7214343
Cited by
Items 701–800 of 1,001
The Microbiome Factor in Drug Discovery and Development
Nuzzo, A., & Brown, J. R. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00333 · Cited by 11
Drug Metabolism as a Community Effort
Hitchings, R., & Kelly, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.005 · Cited by 10
Makkar, S. K., & Bishnupuri, K. S. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1676796 · Cited by 11
Shen, J., Xu, S., Zhao, Q., Zhang, J., & Zhang, H. (2026) · Molecules · doi:10.3390/molecules31040601 · Cited by 11
Zhang, J., Ma, Y., Chang, R., Wang, R., & Zhang, J. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124383 · Cited by 12
Fan, Y., Mansoor, N., Ahmad, T., Wu, Z. X., Khan, R. A., Czejka, M. J., Sharib, S., Ahmed, M., Chen, Z., & Yang, D. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666190212164356 · Cited by 10
Yue, Q., Khojasteh, S. C., Cho, S., Ma, S., Mulder, T., Chen, J. L., Pang, J., Ding, X., Deese, A. J., Pellet, J. D., et al. (2021) · Xenobiotica · doi:10.1080/00498254.2021.1923859 · Cited by 10
Cella, C. A., Ciardiello, D., Gervaso, L., van Laarhoven, H. W. M., Nezi, L., Catozzi, C., Lordick, F., Smyth, E. C., Pascale, S. D., Benini, L., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100048 · Cited by 10
Crosstalk between gut microbiota and cancer chemotherapy: current status and trends
Yang, S., Hao, S., Ye, H., & Zhang, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01704-8 · Cited by 11
Microbial molecules, metabolites, and malignancy
Thomas, R. M. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101128 · Cited by 11
Harnessing the Microbiome to Improve Drug Therapy
Kelly, L. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1510 · Cited by 10
Microbiome and colorectal cancer: A review of the past, present, and future
Johns, M. S., & Petrelli, N. J. (2021) · Surgical Oncology · doi:10.1016/j.suronc.2021.101560 · Cited by 10
Phong, N. V., Min, B. S., Yang, S. Y., & Kim, J. A. (2022) · Applied Sciences · doi:10.3390/app122010685 · Cited by 10
The Influence of the Gut Microbiome in Paediatric Cancer Origin and Treatment
Sági, V., Makra, N., Csoszánszki, N., Decmann, Á., Szabó, D., & Garami, M. (2022) · Antibiotics · doi:10.3390/antibiotics11111521 · Cited by 12
Leardini, D., Venturelli, F., Baccelli, F., Cerasi, S., Muratore, E., Brigidi, P., Pession, A., Prete, A., & Masetti, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315387 · Cited by 12
Decipher enzymes from human microbiota for drug discovery and development
Beliaeva, M. A., Wilmanns, M., & Zimmermann, M. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102567 · Cited by 10
Omics Approaches To Probe Microbiota and Drug Metabolism Interactions
Nichols, R. G., Hume, N. E., Smith, P. B. W., Peters, J. M., & Patterson, A. D. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00236 · Cited by 12
Newman, D. K., & Coleman, M. L. (2011) · Environmental Microbiology Reports · doi:10.1111/j.1758-2229.2010.00236.x · Cited by 10
Canny, S. G. D. L. T., Mueller, O., Craciunescu, C. V., Blumberg, B., & Rawls, J. F. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.09.451869 · Cited by 10
Acarbose impairs gut Bacteroides growth by targeting intracellular glucosidases
Brown, H. A., Morris, A. L., Pudlo, N. A., Hopkins, A. E., Martens, E. C., Golob, J. L., & Koropatkin, N. M. (2024) · mBio · doi:10.1128/mbio.01506-24 · Cited by 9
Rifaximin alleviates irinotecan-induced diarrhea in mice model
Huang, C.-Y., Lan, H., Bai, M., Chen, J., Xu, S., Sun, Q., Chen, Q., Mao, W. B., Jiang, J. F., & Zhu, J. Y. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2429029 · Cited by 9
Computational analysis of the gut microbiota-mediated drug metabolism
Chum, S., Montalvo, A. N., & Hassoun, S. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.03.016 · Cited by 10
Zhou, Y., Jiang, M., Shen, K., He, T., Zhou, S., Shao, A., Li, X., Wang, J., Wu, R., Singla, R. K., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00825-4 · Cited by 10
A drug–microbiome–drug interaction impacts co-prescribed medications for Parkinson’s disease
Verdegaal, A. A., Oh, J., Javdan, B., Wang, R., Wu, Q., Wang, T. R. W., González-Hernández, J. A., Donia, M. S., Crawford, J. M., & Goodman, A. L. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02299-2 · Cited by 9
Multi-omic analysis of host-microbial interactions central to the gut-brain axis
Simpson, J. B., & Redinbo, M. R. (2022) · Molecular Omics · doi:10.1039/d2mo00205a · Cited by 9
Self-citationXu, K., Ying, L., Ying, T., Wu, Q., Du, L., Yu, Y., Ying, Y., Wei, B., Wang, H., & Yang, Z. (2024) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2024.2387415 · Cited by 9
Self-citationĐanić, M., Marković, N., Ostojić, T., Kojic, M., Lazarević, S., Mikov, M., & Pavlović, N. (2024) · BMC Medical Education · doi:10.1186/s12909-024-06249-6 · Cited by 9
The Gut Microbiome in Colorectal Cancer
Piawah, S., Walker, E. J., Blarigan, E. L. V., & Atreya, C. E. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.001 · Cited by 9
Zhang, H., Xu, J., Zhang, X., Wang, T., Zhou, D., Shu, W., Zhao, T., & Fang, W. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.875317 · Cited by 9
The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer
Rogers, S. C., Charles, A. M., & Thomas, R. M. (2023) · Cancers · doi:10.3390/cancers15245708 · Cited by 11
The Modulation of Drug Efficacy and Toxicity by the Gut Microbiome
Wilson, I. D., & Nicholson, J. K. (2014) · Molecular and integrative toxicology · doi:10.1007/978-1-4471-6539-2_15 · Cited by 10
Science in Focus: The Microbiome and Cancer Therapy
Alexander, J. L., Kohoutová, D., & Powell, N. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.09.004 · Cited by 11
Sveistyte, A., Gibbins, T., Tyrrell, K. J., Miller, C. J., Foley, M. H., Plymale, A. E., Wright, A., & Brandvold, K. R. (2020) · ChemBioChem · doi:10.1002/cbic.202000370 · Cited by 9
Advance in oral delivery of living material
Liu, H., Fan, Y., Zhong, J. P., Malkoch, M., Cai, Z., & Wang, Z. (2023) · Biomedical Technology · doi:10.1016/j.bmt.2022.12.003 · Cited by 9
Synthesis and evaluation of galacto-noeurostegine and its 2-deoxy analogue as glycosidase inhibitors
Salamone, S., Clement, L. L., Viuff, A. H., Andersen, O. J., Jensen, F., & Jensen, H. H. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob01062d · Cited by 9
Wang, X., Lyu, Y., Cheng, S. W., Tsang, T. F., Chong, K. C., Boon, S. S., Yang, X., Lai, C. K. C., Chan, P. K. S., & Zuo, Z. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116717 · Cited by 9
Microbiota mechanisms in cancer progression and therapy
Zhang, X., Fam, K. T., Dai, T., & Hang, H. C. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.005 · Cited by 9
Xie, H., Yang, J., Wu, J., Ma, W., Xu, H., Guo, S., Xie, Y., Luo, Z., Liang, D., Cao, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68741-5 · Cited by 8
The Anti- and Pro-Tumorigenic Role of Microbiota and Its Role in Anticancer Therapeutic Strategies
Greco, G., Zeppa, S. D., Agostini, D., Attisani, G., Stefanelli, C., Ferrini, F., Sestili, P., & Fimognari, C. (2022) · Cancers · doi:10.3390/cancers15010190 · Cited by 9
Advanced piperazine-containing inhibitors target microbial β-glucuronidases linked to gut toxicity
Graboski, A. L., Simpson, J. B., Pellock, S. J., Mehta, N., Creekmore, B. C., Ariyarathna, Y., Bhatt, A. P., Jariwala, P. B., Sekela, J. J., Kowalewski, M. E., et al. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00058g · Cited by 8
Self-citationHan, Y., Liu, Y.-T., Lu, C., Sun, H.-F., Zhu, G., Kang, D.-N., Zhou, Q., Tang, H., Yin, Y.-L., & Hou, J. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111261 · Cited by 8
Zhou, T., He, L., He, J., Yang, Z., Zhou, Z., Du, A., Yu, J., Li, Y., Wang, S., Wei, B., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105306 · Cited by 8
Self-citationBioaccumulation as a mechanism of microbiome/drug interactions
Cohen, Z., & Kelly, L. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.12.003 · Cited by 8
Rao, G., Yu, H., Zhang, M., Cheng, Y., Ran, K., Wang, J., Wei, B., Li, M., Shan, W., Zhan, Z., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15030329 · Cited by 8
Li, P., Chen, Q., Wang, Y., & Min-wen, H. (2014) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2013.0494 · Cited by 8
Craig, D. B., King, S. D., Reinfelds, G., Henderson, A., & Wood, T. E. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.12.034 · Cited by 8
Promising Chemotherapy for Malignant Pediatric Brain Tumor in Recent Biological Insights
Zhou, Q., Xu, Y., Zhou, Y., & Wang, J. (2022) · Molecules · doi:10.3390/molecules27092685 · Cited by 9
Total and Diverted Total Synthesis of Pyrrolo‐Quinazolinone Alkaloids and Their Analogues
Rasapalli, S., Huang, Y., Sammeta, V. R., Alshehry, R., Anver, F., Shivasankar, K., & Chavan, S. P. (2023) · ChemistrySelect · doi:10.1002/slct.202301818 · Cited by 8
Yousuf, M., Shaikh, N. N., Ul‐Haq, Z., & Choudhary, M. I. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200502 · Cited by 9
Ling Zhi, X. I. A. O., Chi, D., Sheng, G., Li, W., Lin, P., Liang, S., Zhu, L., & Dong, P. (2020) · RSC Advances · doi:10.1039/d0ra02311f · Cited by 8
The Impact of Microbiome on Breast Cancer and Regulatory Strategies
Wang, J., Xu, D., Hu, S., Zheng, B., Chen, Y., & Pan, T. (2025) · Microorganisms · doi:10.3390/microorganisms14010075 · Cited by 10
Chen, Y., Du, H., Zhou, W., Qin, M., Li, M., Jin, Y., Xu, Y., Ma, C., Xia, J., Mo, Y., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2025.2610077 · Cited by 8
Xia, L.-J., Wan, L., Gao, A., Yu, Y.-X., Zhou, S., He, Q., Li, G., Ren, H., Lian, X., Zhao, D., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130145 · Cited by 7
Microbiome‐driven anticancer therapy: A step forward from natural products
Guan, Y., Wu, D., Wang, H., & Liu, N. (2024) · mLife · doi:10.1002/mlf2.12118 · Cited by 8
Self-citationLiu, Q., Yang, Y., Pan, M., Shi, K., Mo, D., Li, Y., Wang, M., Guo, L., & Qian, Z. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.07.032 · Cited by 7
Palkovský, M., Modráčková, N., Bunešová, V., Liberko, M., & Soumarová, R. (2024) · In Vivo · doi:10.21873/invivo.13803 · Cited by 8
Phong, N. V., Yang, S. Y., Han, K.-H., Min, B. S., & Kim, J. A. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.141433 · Cited by 7
Wu, Q., Guo, Q., Yang, F., Li, M., Zhu, Y., Xu, B., Zhao, L., Zhang, S., Xie, Y., Li, F., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13051043 · Cited by 7
Pharmacology in the age of the holobiont
Norvaišas, P., & Cabreiro, F. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.05.006 · Cited by 8
Wang, Q., Lu, D., Liu, H., & Li, C. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c06859 · Cited by 7
Chatzigeorgiou, S., Jílková, J., Korecká, L., Janyšková, R., Hermannová, M., Šimek, M., Čožíková, D., Slováková, M., Bílková, Z., Bobek, J., et al. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.121078 · Cited by 7
Khezri, M. R., Esmaeili, A., & Ghasemnejad‐Berenji, M. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00418 · Cited by 8
Insights Into the Relationship Between Gut Microbiota and Colorectal Cancer
Mota, J. F., Walter, J., & Prado, C. M. M. (2018) · Current Colorectal Cancer Reports · doi:10.1007/s11888-018-0419-4 · Cited by 7
Dashnyam, P., Lin, H., Chen, C.-Y., Gao, S., Yeh, L.-F., Hsieh, W., Tu, Z., & Lin, C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01918 · Cited by 7
Self-citationAshtekar, N., Anand, G., Prakash, P. Y., & Rajeshkumar, K. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821005-5.00015-6 · Cited by 7
Emerging trends in aggregation induced emissive luminogens as bacterial theranostics
KUMARI, R. R., & Sunil, D. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1888111 · Cited by 7
The microbiome and precision oncology: an emerging paradigm in anticancer therapy
Bhat, S. A., Kaur, R., Chauhan, A., & Pal, A. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2035313 · Cited by 8
Xenobiotics and drug-metabolizing enzymes: Challenges and strategies
Sayyed, Y., Rehman, K., Akash, M. S. H., Kamran, S. H., & Badran, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95120-3.00007-5 · Cited by 9
The Role of the Microbiome in Inflammation and Carcinogenesis
Jabłońska‐Trypuć, A. (2023) · Frontiers in Bioscience-Elite · doi:10.31083/j.fbe1504028 · Cited by 7
Ülker, B., Hommelsheim, C. M., Berson, T., Thomas, S., Chandrasekar, B., Olcay, A. C., Berendzen, K. W., & Frantzeskakis, L. (2012) · The Plant Cell · doi:10.1105/tpc.112.100404 · Cited by 8
Increased activity of β -glucuronidase variants produced by site-directed mutagenesis
Zhang, X., Sitasuwan, P., Horvath, G. C., Yang, J., Nie, Y., Marinova, M. D., Lee, L. A., & Wang, Q. (2017) · Enzyme and Microbial Technology · doi:10.1016/j.enzmictec.2017.09.005 · Cited by 7
Epithelial delamination is protective during pharmaceutical-induced enteropathy
Espenschied, S. T., Cronan, M. R., Matty, M. A., Mueller, O., Redinbo, M. R., Tobin, D. M., & Rawls, J. F. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902596116 · Cited by 7
Self-citationKim, J. H., Vinh, L. B., Hur, M., Koo, S.-C., Park, W. T., Moon, Y.-H., Lee, Y. J., Kim, Y. H., Huh, Y.-C., & Yang, S. Y. (2021) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2108.08004 · Cited by 7
Drugs and gut microbiome interactions—an emerging field of tailored medicine
Khan, I. (2023) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-023-00684-9 · Cited by 8
Multifaceted effects of the microbiome in pancreatic cancer: from association to modulation
Thomas, R. M. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01119-y · Cited by 6
Hsu, C.-Y., Almajidi, Y. Q., Abohassan, M., Refatovich, G. R., Basunduwah, T. S., Hjazi, A. M., Arora, V., Nayak, P. P., Shukla, S. K., & Jayabalan, K. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105229 · Cited by 6
Gut microbiota alters drug metabolism and therapeutic outcomes
Guo, F., Bai, Y., & Lei, X. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.06.001 · Cited by 7
Lee, G., Rosa, B. A., Fernández-Baca, M. V., Martin, J. C., Ore, R. A., Ortiz, P., Cabada, M. M., & Mitreva, M. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1555171 · Cited by 6
The promising path of Oral MOFs: Redefining strategies for gastrointestinal detoxification
Quan, Y., Wu, Y., Wang, K., Ren, H., Zhang, G., Zhao, Y., & Miao, Y. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217168 · Cited by 6
Glioblastoma as a Novel Drug Repositioning Target: Updated State
Hosseinalizadeh, H., Ebrahimi, A., Tavakoli, A., & Monavari, S. H. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230202163112 · Cited by 6
Forging the microbiome to help us live long and prosper
Rock, R. R., & Turnbaugh, P. J. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002087 · Cited by 7
Herbal Medicines as Adjuvants for the Treatment of Chemotherapy-Induced Diarrhea
Zheng, Z., Srinual, S., Chen, J., Li, L., Du, T., Hu, M., Sun, R., & Gao, S. (2023) · Current Drug Metabolism · doi:10.2174/1389200224666230817102224 · Cited by 6
Gut microbiome and bladder cancer: A new link through nitrosamine metabolism
Mani, S. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.09.003 · Cited by 6
Self-citationEffects of PD-1/PD-L1 signaling pathway on intestinal flora in patients with colorectal cancer
Pi, H., Huang, L., Liu, H., Liang, S., & Mei, J. (2020) · Cancer Biomarkers · doi:10.3233/cbm-201606 · Cited by 6
Bélanger, V., Benmoussa, A., Napartuk, M., Warin, A., Laverdière, C., Marcoux, S., Levy, E. H., & Marcil, V. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8143 · Cited by 8
Becker, H. E. F., Penders, J., & Jonkers, D. M. A. E. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.050 · Cited by 6
Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Rana, D., Salave, S., Perla, A., Nadkarni, A., Kolhe, S., Jindal, A. B., Mandoli, A., Dwivedi, P., & Benival, D. M. (2022) · Current Drug Targets · doi:10.2174/1389450123666220309101345 · Cited by 6
Lachkar, M., Halime, I., Bezgour, A., Bali, B. E., Dušek, M., Fejfarová, K., Siddiq, S., Marasini, B. P., Noreen, S., Khan, A., et al. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-011-9968-7 · Cited by 6
Improving the activity and thermostability of GH2 β‐glucuronidases via domain reassembly
Liu, M., Yu, J., Lv, B., Hou, Y., Liu, X., Feng, X., & Li, C. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27710 · Cited by 6
Microbe defines the efficacy of chemotherapeutic drug: a complete paradigm
Dalal, P., & Sharma, D. (2021) · FEMS Microbiology Letters · doi:10.1093/femsle/fnab116 · Cited by 6
Chemoproteomic Approaches for Unraveling Prokaryotic Biology
Malarney, K. P., & Chang, P. V. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202200076 · Cited by 7
Burin, R., & Shah, D. H. (2021) · Pathogens · doi:10.3390/pathogens10040469 · Cited by 5
He, Y. M., Li, X., Hu, A.-Q., & Qian, D. (2024) · Journal of Oral Microbiology · doi:10.1080/20002297.2024.2359887 · Cited by 5
Tarushi, Gupta, G. D., Kumar, M., & Bihani, S. C. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2496291 · Cited by 6
Emerging Tools and Technologies for Microbiome‐Aware Drug Development
Haiser, H. J., & de Gruijl, D. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70026 · Cited by 5
The microbiome and lung cancer: microbial effects on host immune responses and treatment outcomes
Bailey, A., Leuther, K. K., & Robinson, L. A. (2025) · Frontiers in Microbiomes · doi:10.3389/frmbi.2025.1606551 · Cited by 5
Clinical Detection and Management of Colorectal Cancer Concerning the Gut Microbiome
Farahani, H. E., Pourhajibagher, M., & Bahador, A. (2025) · Scientifica · doi:10.1155/sci5/1945321 · Cited by 6
Hydrolysis of O-, N-, and N+-glucuronide metabolites in human feces
Zhang, Z., Chen, A., & Hariparsad, N. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100163 · Cited by 5
Personalized nutrition, personalized medicine, and microbiome therapeutics
Chauhan, N. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00017-3 · Cited by 13
Metadata
- Authors
- Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., & Redinbo, M. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Albert Einstein College of Medicine (US)
- North Carolina Central University (US)
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 831-835
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3110694
- OpenAlex
- W2140145798
- Cited by
- 1,080
- References
- 39
- Citations by year
- 2026: 97 · 2025: 80 · 2024: 103 · 2023: 101 · 2022: 92 · 2021: 92 · 2020: 100 · 2019: 82 · 2018: 70 · 2017: 67 · 2016: 47 · 2015: 33 · 2014: 34 · 2013: 28 · 2012: 29
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Damon Runyon Cancer Research Foundation
- Golden LEAF Foundation
- National Institutes of Health
- National Cancer Institute (CA 127231, R01CA161879, R01CA127231, CA98468, R01CA098468)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073338)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, chemotherapy-induced diarrhea, enzyme inhibitors, gut microbiota, commensal bacteria, substrate specificity, crystal structure, high-throughput screening, oral administration, colon cancer, drug toxicity
- MeSH terms
- Irinotecan, Animals, Antineoplastic Agents, Phytogenic, Bacteria, Anaerobic, Camptothecin, Colon, Diarrhea, Drug Evaluation, Preclinical, Enzyme Inhibitors, Escherichia coli, Female, Glucuronidase, Humans, Intestinal Mucosa, Mice, Inbred BALB C, Models, Molecular, Prodrugs, Protein Conformation, Crystallography, X-Ray, Escherichia coli Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.